Iterum Therapeutics Strategizes for NASDAQ Compliance and FDA Review
Company Announcements

Iterum Therapeutics Strategizes for NASDAQ Compliance and FDA Review

Iterum Therapeutics (ITRM) has shared an update.

Iterum Therapeutics International Limited has contracted its outgoing Chief Medical Officer, Dr. Sailaja Puttagunta, as a consultant during the regulatory review of its new drug application for a urinary tract infection treatment. Dr. Puttagunta will be compensated at $400 per hour. Concurrently, the company is striving to regain compliance with Nasdaq Listing Rule 5550(b)(1) after being notified of a deficit in stockholders’ equity, with a deadline of September 30, 2024, to avoid delisting. Additionally, the FDA has acknowledged the resubmission of the company’s new drug application and set a review deadline for October 25, 2024.

For detailed information about ITRM stock, go to TipRanks’ Stock Analysis page.

Related Articles
Sheryl Sheth3 Penny Stocks to Watch Now, 10/29/24
TheFlyBiotech Alert: Searches spiking for these stocks today
TipRanks Auto-Generated NewsdeskIterum Therapeutics Gains FDA Approval for ORLYNVAH
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App